Biotech firm Oxford Nanopore has raised £100m from its latest private funding round, valuing the rapidly-expanding UK group somewhere in the vicinity of £1.5bn as a result.
Autifony Therapeutics, a spin-out from GlaxoSmithKline backed by IP Group, has signed a 627.5m central nervous system collaboration with German drugs giant Boehringer Ingelheim.
Mirriad Advertising, a video technology company backed by IP Group plans to float on London's AIM with a £26.2m fundraising to speed its expansion.
IP Group updated the market again on its takeover offer for Touchstone Innovations on Wednesday, confirming that as at 1300 BST on Tuesday, it had received valid acceptances of its offer in respect of 155,859,312 Touchstone shares, representing 96.6844% of Touchstone's issued share capital.
IP Group's offer for Touchstone Innovations was back on track on Tuesday morning, following a statement from the Competition and Markets Authority confirming that the competition watchdog had decided not to refer the merger to a Phase 2 investigation.
IP Group updated the market on its takeover offer for Touchstone Innovations on Monday, confirming an extension to its offer deadline, and confirming it has received support for the offer from shareholders representing more than 97% of Touchstone shares in issue.
Intellectual property-based business IP Group noted on Wednesday morning that Istesso, formerly Modern Biosciences, has announced new data from a cohort of patients dosed as part of a phase 1 study of MBS2320, its investigational drug for the treatment of rheumatoid arthritis.
IP Group announced on Tuesday that its majority owned subsidiary Istesso had completed a successful first round of dosing in a Phase 2a study of a potential rheumatoid arthritis drug.
IP Group said a proposed capital raising in China had been hit by new regulatory controls in the People's Republic.
Intellectual property-business IP Group said on Friday that its portfolio company, Tissue Regenix, has raised £40m through a placing and subscription of new ordinary shares as it announced the acquisition of CellRight Technologies.
Intellectual property-based business developer IP Group saw its net assets grow to £968.1m in its first half, it reported on Tuesday, from £748.5m year-on-year, while its hard net asset value was firmer at £890.5m, from £683.5m 12 months earlier.
Intellectual property-based business IP Group noted on Monday that its portfolio company, Creavo Medical Technologies, had completed a fundraising of £13.4m.
David Newlands, chairman of the board at Touchstone Innovations, wrote to shareholders on Thursday outlining a number of concerns over a recent approach from IP Group to combine the two businesses.
Touchstone Innovations on Tuesday confirmed IP Group's merger approach, adding that it had advised shareholders to take no action.
Intellectual property-based business developer IP Group said it had made an offer for Touchstone Innovations and was also planning to raise £200m in a cash call.
Intellectual property-based business developer IP Group issued a statement on Wednesday morning, updating the market on its position and progress since 31 December, as investors headed for the company's London offices for the annual general meeting in the afternoon.
Developer of intellectual property-based businesses IP Group noted on Wednesday that its portfolio company, Ultrahaptics, had completed a fundraising of £17.9m.
Intellectual property-based business developer IP Group announced its annual financial results for the year to 31 December on Tuesday, with an overall net increase in the fair value of its portfolio, excluding net investment, of £6.5m - weakening from the £86.2m improvement in 2015.
Intellectual property-based business developer IP Group noted on Wednesday that its portfolio company Actual Experience raised a total of £17.5m before expenses, by means of a conditional placing.
IP Group, the developer of intellectual property-based businesses, said its first two portfolio companies from US university partners had raised a combined £5.4m ($6.8m) in new post seed financing rounds via private placement of ordinary shares.